Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS

The Comprehensive Prostate Center

Nashville, TN

Raoul S. Concepcion, MD, FACS, is the current Medical Director of The Comprehensive Prostate Center in Nashville TN and also a Clinical Assistant Professor in the Department of Urology, Vanderbilt School of Medicine. He is a Past President of the Large Urology Group Practice Association (LUGPA), a not for profit entity representing the interests of over 2,500 urologists in the U.S. affiliated with large single specialty groups. Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984-1989. He served as Chief Urology Resident from 1989-1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society. From a research perspective, Dr. Concepcion has been actively in involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990’s (see enclosed CV). The focus as of recent has been in the Castration Resistant Prostate Cancer (CRPC) patients, as well as biomarker development. Along with two other urologists, he recently started CUSP, a Urology Specific Clinical Trials Organization that specializes in site and patient accrual for the pharmaceutical and bio lab industries.

Articles by Raoul S. Concepcion, MD, FACS

Immunotherapy 101 for the Urologist

Raoul S. Concepcion, MD, summarizes the mechanism of action behind the immune response to cancer. He also provides an update on the current and emerging immunotherapies for cancer treatment, including vaccines, checkpoint inhibitors, CAR T-cell therapies, viral vectors, and adoptive cell therapy.

Read More

Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?

Raoul S. Concepcion, MD, FACS, discusses managing prostate cancer with a combination of immunotherapeutic agents and other treatment options. Sipuleucel-T (PROVENGE), the only FDA approved immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), does not attack androgen receptors. Therefore, Dr. Concepcion explores the possibility combining sipuleucel-T with androgen excess inhibitors, like abiraterone or enzalutamide, or a sipuleucel-T/radium-223 combination.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -